Evolution of PCSK9 inhibitors: Pipedream or Evidence based RealityHow do we recognize FH in clinical practice?PCSK9 Inhibitors: A View of Clinical StudiesFH in children and adolescentsALN-PCSsc: Initial Phase 1 Study ResultsView all slides »
Is lowering lipoprotein(a) beneficial when LDL-C is very low?
How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes
What’s in the PCSK9 pipeline?
EAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?View all videos »